| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1028228182 |
| P356 | DOI | 10.1186/S13046-016-0380-5 |
| P3181 | OpenCitations bibliographic resource ID | 338496 |
| P932 | PMC publication ID | 4928292 |
| P698 | PubMed publication ID | 27357210 |
| P2093 | author name string | Francesco Cognetti | |
| Alessandra Fabi | |||
| Sabrina Vari | |||
| Paola Malaguti | |||
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group | Q27824835 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. | Q27851468 | ||
| PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. | Q27851582 | ||
| Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
| Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer | Q27852071 | ||
| Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer | Q27853134 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies | Q28067499 | ||
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 | ||
| Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. | Q30814798 | ||
| A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy | Q33410791 | ||
| Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer | Q33410989 | ||
| Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer | Q33414335 | ||
| FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer | Q33415631 | ||
| Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review | Q33561966 | ||
| AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models | Q33770856 | ||
| Role of HER2 gene overexpression in breast carcinoma | Q33810080 | ||
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. | Q33827808 | ||
| Sequence analysis of mutations and translocations across breast cancer subtypes | Q34032470 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Molecular signatures of lymph node status by intrinsic subtype: gene expression analysis of primary breast tumors from patients with and without metastatic lymph nodes | Q35066446 | ||
| Treatment of HER2-positive breast cancer. | Q35740877 | ||
| Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer | Q35987082 | ||
| Targeting Her-2/neu in breast cancer: as easy as this! | Q37245691 | ||
| Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer | Q37387449 | ||
| Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. | Q51327778 | ||
| Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. | Q53426459 | ||
| Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. | Q54342129 | ||
| Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. | Q54566127 | ||
| CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. | Q55068564 | ||
| Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors | Q58849618 | ||
| Clinical implementation of the intrinsic subtypes of breast cancer | Q59565395 | ||
| Clinical Utility of Continuing Trastuzumab Beyond Brain Progression in HER-2 Positive Metastatic Breast Cancer | Q62581294 | ||
| HER2 inhibition: from discovery to clinical practice | Q79476874 | ||
| Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study | Q80574611 | ||
| Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab | Q81151636 | ||
| Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM | Q84592604 | ||
| HER-2-positive metastatic breast cancer: trastuzumab and beyond | Q94706721 | ||
| Early-onset colorectal cancer patients without family history are "at very low risk" for lynch syndrome | Q37479736 | ||
| Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. | Q37489025 | ||
| Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer | Q37716326 | ||
| New target therapies for brain metastases from breast cancer | Q37977974 | ||
| Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. | Q38080898 | ||
| Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline | Q38209628 | ||
| Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial | Q38393636 | ||
| Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models | Q39771295 | ||
| Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors | Q40059109 | ||
| Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. | Q40073729 | ||
| Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy | Q40138970 | ||
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 | ||
| Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer | Q41134799 | ||
| Activity of T-DM1 in Her2-positive breast cancer brain metastases | Q41455800 | ||
| Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. | Q41655720 | ||
| Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer | Q43270036 | ||
| Breast cancer brain metastases responding to primary systemic therapy with T-DM1. | Q43621364 | ||
| Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer | Q43937165 | ||
| Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study | Q46256397 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metastatic breast cancer | Q12859063 |
| Erb-b2 receptor tyrosine kinase 2 | Q415271 | ||
| breast neoplasm | Q23929670 | ||
| antineoplastic combined chemotherapy protocols | Q66764603 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 104 | |
| P577 | publication date | 2016-06-30 | |
| P1433 | published in | Journal of Experimental & Clinical Cancer Research | Q13739415 |
| P1476 | title | First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces? | |
| P478 | volume | 35 |
| Q90482919 | Administration of trastuzumab with heart irradiation induced acute cardiotoxicity in mice |
| Q42377436 | Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification |
| Q57111760 | Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This? |
| Q52627331 | Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells. |
| Q47435154 | Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis |
| Q90412342 | HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases |
| Q59340503 | Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis |
| Q42374085 | Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis. |
| Q91739070 | Prognostic phenotypic classification for canine mammary tumors |
| Q49592680 | Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy |
| Q50333939 | Recombinant nanocomposites by the clinical drugs of Abraxane® and Herceptin® as sequentially dual-targeting therapeutics for breast cancer |
| Q47123520 | Short course hypofractionated whole breast irradiation after conservative surgery: a single institution phase II study. |
| Q33755476 | Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives. |
| Q47141830 | Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. |
| Q54979386 | Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. |
Search more.